Navigation Links
Questcor Reports First Quarter Financial Results
Date:4/30/2013

al measures are provided with the financial tables included with this release.

"Our first quarter results were below our expectations," said Don M. Bailey, President and CEO of Questcor. "However, vial shipment activity and prescription levels in MS and rheumatology in late March and throughout April appear to indicate that positive sales momentum has returned. In particular, we note that our newest initiative related to the promotion of Acthar for dematomyositis and polymyositis is off to a strong start."

Mr. Bailey continued, "In the first quarter, we made several operational changes aimed at ensuring and improving the delivery of Acthar for patients who rely on this important drug. We continue to seek to improve our business operations in order to benefit both Acthar patients and our shareholders by establishing a solid foundation for potential additional growth."

"Total new paid prescriptions for Acthar were approximately 1,725 to 1,750 in the first quarter, an increase of about 16% year-over-year and a decrease of about 9% sequentially," commented Steve Cartt, Chief Operating Officer of Questcor. "New paid prescriptions for NS, which represent about half of our Acthar business, were about 385-395 in the quarter, up about 56% year-over-year and up about 5% over the fourth quarter of 2012. New paid prescriptions for MS, which represent about a quarter of our Acthar business, were about 1,015 to 1,025, roughly flat year-over-year and down 17% from the prior quarter. New paid prescriptions for IS were 155 to 165. Net sales related to IS were positively influenced by the reduction of the Medicaid rebate in the quarter. New paid prescriptions for the on-label rheumatology indications were 140-150, up about 58% sequentially."

Mr. Cartt continued, "Consistent with the level of our vial sales in April, new paid prescription activity in April has been robust. While the second quarter is only about one-third complete, NS continues to grow, MS i
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Questcor to Report First Quarter Results on April 30, 2013
2. Questcor Reports Fourth Quarter and Full Year 2012 Results
3. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
4. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
5. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
6. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Questcor Comments on Insurance Policy Bulletin
9. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
10. Questcor Pharmaceuticals to Present at Investor Conferences in September
11. Questcor Reports Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... DALLAS and NEW YORK ... PHARMACEUTICALS, INC. (OTCBB: ACCP), has signed an exclusive, ... for the development and commercialization of its proprietary ... new corporate management team and its intention to ... Biopharmaceuticals, Inc.™, and its plans to pursue a ...
(Date:9/22/2014)... DENVER , Sept. 22, 2014  Prostate cancer ... men, but it is easily treated when caught early ... not. That is why the Prostate Conditions Education ... men,s health and a leader in prostate cancer screening ... Cancer Awareness Week (PCAW) from September 22-27.  ...
Breaking Medicine Technology:Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3
... Patent Protects Very Low Dose Glucagon ahead of Phase 2 Clinical Trials ... ... SAN FRANCISCO, Jan. 8 DiObex, Inc., a privately held,biotechnology company developing ... from the U.S. Patent,and Trademark Office for the use of very low ...
... BOTHELL, Wash., Jan. 8 Nastech Pharmaceutical,Company Inc. ... enrollment for its,Phase 2 clinical trial of PYY3-36 ... obese patients at multiple clinical sites in the ... study. The,study is designed to evaluate three different ...
Cached Medicine Technology:DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia 2Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity 2Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity 3
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... living in Canada have a higher rate of heart ... while people, McMaster researchers have found. , The ... Association Journal (CMAJ Open) and may be found ... ethnic groups in the country is the more than ... about three percent of the population. They include people ...
(Date:9/22/2014)... -- Recent two-generation approaches to reducing poverty that ... attention from researchers, advocates, and foundations. By combining ... to move to jobs that offer a path ... education for children, these programs aim to improve ... to a new report from the National Center ...
(Date:9/22/2014)... 22, 2014 The R&D of cancer ... years. The statistically important data received from clinical research ... vaccines. The primary challenge to the development of such ... exact mechanism of how a human’s immune system works. ... in different individuals owing to known factors with genetics ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
Breaking Medicine News(10 mins):Health News:Looking ahead: Whole eye transplant under development 2Health News:Higher risk of heart disease for South Asians in Canada 2Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2
... Researchers and staff from Karolinska Institutet are contributing ... of everything from neuroscience to bioentrepreneurship. Carl Johan ... Institutet, is the founder and initiator of ESOF. ... decision-makers, researchers, journalists and the general public meet ...
... ... dedicated to ending malaria deaths and empowering communities, ONE bracelet at a time (Buy a ... Malaria, and encourages others to join in the fight against this deadly disease. Malaria is ... kills a child every 30 seconds. , ...
... suggests that shorter length of leukocyte telomeres chromosome markers ... of cancer and death from cancer, according to a study ... leukocyte is a type of blood cell. Telomeres are ... the replication and stability of the chromosome. Genetic factors and ...
... COLUMBUS, Ohio Scientists have designed a nanoparticle that appears ... effects. In lab experiments, the researchers have found that ... enough into a cell to allow genetic material to be ... is between 2 and 10 times more effective than ...
... linked rejection by a romantic partner to brain activity associated ... published in the July issue of the Journal of ... R. Korey Department of Neurology and of neuroscience at Albert ... author of the study. This is the third publication in ...
... ... of additional foot problems such as bunions, hammertoes, arthritis and calluses, and improve a ... Ankle Surgery. , ... Chicago, IL (Vocus) July 6, 2010 -- Treatment and prevention of adult flatfoot can ...
Cached Medicine News:Health News:News from Karolinska Institutet at ESOF 2010 2Health News:MALAIKA FOR LIFE Takes a Stand in Light of Cheryl Cole's Malaria Bout 2Health News:MALAIKA FOR LIFE Takes a Stand in Light of Cheryl Cole's Malaria Bout 3Health News:Length of biological marker associated with risk of cancer 2Health News:Scientists design new delivery device for gene therapy 2Health News:Scientists design new delivery device for gene therapy 3Health News:Scientists design new delivery device for gene therapy 4Health News:Study links romantic rejection with reward and addiction centers in the brain 2Health News:Don't Ignore Flat Feet,Study links this condition to painful foot maladies 2
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Rigid Endoscopes....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: